Disclosed is an isolated antibody or antigen-binding fragment thereof specifically binding to the extracellular N-terminal epitope (RPSFSLVEDTTLEPE) of FGFR2 as presented by SEQ ID NO:63. Also disclosed is the use of said antibody or antigen-binding fragment in the manufacture of a medicament for the treatment of cancer.